308080 — ViGenCell Balance Sheet
0.000.00%
- KR₩126bn
- KR₩94bn
- KR₩279m
Annual balance sheet for ViGenCell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16,185 | 65,448 | 69,074 | 53,412 | 45,183 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,145 | 103 | 743 | 850 | 627 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17,660 | 66,724 | 69,892 | 54,442 | 45,877 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,824 | 16,120 | 26,968 | 23,498 | 18,818 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 23,051 | 116,979 | 99,373 | 81,049 | 67,346 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 56,314 | 10,189 | 8,353 | 8,474 | 8,002 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 57,122 | 12,091 | 9,731 | 9,560 | 9,321 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | -34,072 | 104,887 | 89,643 | 71,489 | 58,026 |
| Total Liabilities & Shareholders' Equity | 23,051 | 116,979 | 99,373 | 81,049 | 67,346 |
| Total Common Shares Outstanding |